significant effect of raloxifene on bone in hemodialysis patients

نویسندگان

pernille ravn department of gynecology and obstetrics, gynecologic-endocrinology unit, odense university hospital, denmark +45-65411260, [email protected]; department of gynecology and obstetrics, gynecologic-endocrinology unit, odense university hospital, denmark +45-65411260, [email protected]

چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Significant Effect of Raloxifene on Bone in Hemodialysis Patients

Attention should be drawn to the study by colleagues Saito O et al. published in the International journal of Endocrinology and Metabolism (1). The study suggests that raloxifene has a significant beneficial effect on bone in postmenopausal women with type 2 diabetes (2DM) undergoing hemodialysis (1). Hemodialysis patients are known to have a high risk of low bone mineral density and bone fract...

متن کامل

Effects of Raloxifene on Bone Metabolism in Hemodialysis Patients

Saito et al. (1) reported that raloxifene (RAL) suppressed bone turnover and increased the quantitative ultrasound (QUS) parameter, speed of sound (SOS) of the calcaneus in hemodialysis postmenopausal women with type 2 diabetes or without type 2 diabetes. Baseline bone turnover markers like serum cross-linked N-terminal telopeptides of type I collagen (NTX) and bone-specific alkaline phosphatas...

متن کامل

Safety of Raloxifene in Hemodialysis Patients

With interest I read the article from Saito and colleagues about “the effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes” (1). The article addresses the possibility of treatment with raloxifene for osteoporosis in these patients. Raloxifene, a selective estrogen receptor modulator could be a good option, because it has no known renal side effects like bisphos...

متن کامل

Effects of Raloxifene on Bone Metabolism in Hemodialysis Patients With Type 2 Diabetes

BACKGROUND Osteoporosis and chronic kidney disease are common conditions in older adults, and often occur concurrently. Bone disease is caused by increased bone turnover accompanying secondary hyperparathyroidism, and by factors such as bone metabolic disorder accompanying kidney disease and postmenopausal or age-related osteoporosis, even in hemodialysis patients. Raloxifene is commonly used f...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
international journal of endocrinology and metabolism

جلد ۱۰، شماره ۴، صفحات ۶۳۶-۶۳۷

کلمات کلیدی

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023